Investigations in a variety of cancer types with a range of chemotherapy agents have reported greater efficacy of chemotherapy when marine n-3 long-chain polyunsaturated fatty acids (LCPUFAs) are added to the diet ([@bib25]). The mechanisms of action of these antineoplastic agents vary, suggesting that n-3 LCPUFAs modulate responses via diverse range of mechanisms. The n-3 LCPUFAs are also suggested to have antitumour effects including inhibition of angiogenesis and metastasis ([@bib4]); however, the specific mechanisms behind these effects have not been elucidated. Furthermore, n-3 LCPUFAs have been implicated in decreasing the severity of secondary cancer complications including cancer cachexia. Regardless of the exact mechanisms, previous studies suggest that n-3 LCPUFAs may have potential as an effective adjuvant to chemotherapy treatment, may have direct anticancer effects, and may help to ameliorate some of the secondary complications associated with cancer. In this review we briefly describe the chemical structure of n-3 LCPUFAs, the anticancer effects associated with their use in cancer patients, and some of the potential benefits they may have in patients who develop cancer cachexia.

Marine PUFAs
============

Marine PUFAs are divided into two classes: omega-3 (n-3) and omega-6 (n-6); the n-3 and n-6 indicate the position of the first double bond with regard to the terminal methyl end of the molecule ([@bib19]). The n-3 and n-6 PUFAs are stored in membrane phospholipids ([@bib34]), and are responsible for numerous cellular functions including cell membrane structure, fluidity, signalling, and cell-to-cell interaction ([@bib10]). They also regulate other bodily functions including blood pressure, blood clotting, and nervous system function and development ([@bib40]). The n-3 and n-6 fatty acids are considered to be essential nutrients and are required in the diet. Although the synthesis of longer, more saturated n-3 fatty acids within human tissues is possible when provided with the precursor linolenic acid, the rate of synthesis to longer more unsaturated fatty acids in humans is limited ([@bib34]). Eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3) are long-chain n-3 fatty acids ([@bib19]) found in all fish species, with oily fish from cold climates containing the highest levels of EPA and DHA, although levels differ depending on a number of factors such as environment and fat content ([@bib40]).

Arachidonic acid (AA) is a major intermediate derived from n-6 fatty acids that competes for the same metabolic pathway as EPA, as they are both catalysed by the same enzymes ([@bib34]), and therefore when high levels of EPA are consumed in the diet, AA levels are reduced and in part substituted by EPA ([@bib40]). The reverse also occurs when high levels of AA or low levels of EPA are consumed in the diet ([@bib40]). In addition to playing important roles in cellular and bodily functions, n-3 and n-6 are precursors to eicosanoids that have a vital function in regulating inflammatory processes ([@bib40]). Polyunsaturated fatty acids are stored in cellular membranes, and are released via hydrolysis and esterification by phospholipase A~2~ (PLA~2~) before metabolism into eicosanoids ([@bib34]). Eicosanoids can be divided into four categories: prostaglandins, thromboxanes, leukotrienes, and hydroxyeicosatetraenoic acids ([@bib40]), which differ in action depending on if they are a derivative of AA or EPA. Eicosanoids from AA are responsible for inducing pro-inflammatory, pro-arrhythmic, and vasoconstrictive responses, whereas eicosanoids from EPA have the contrasting effects of anti-inflammatory, anti-arrhythmia, and vasodilative responses ([@bib34]).

Anticancer actions of marine PUFAs
==================================

Both EPA and DHA have received much attention recently because of the emergence of studies reporting their effects as broad-spectrum health-promoting agents, including their use in the prevention and treatment of cancer. [Table 1](#tbl1){ref-type="table"} summaries key clinical studies that have investigated the use of n-3 LCPUFAs in the treatment of cancer and treatment or prevention of cachexia.

Many epidemiological studies have suggested that a diet high in n-3 LCPUFA, such as the Japanese and Mediterranean diets, has lower incidences of cancer ([@bib4]; [@bib17]). Although it is difficult to draw solid conclusions regarding their benefit from epidemiological studies, prospective studies assessing n-3 LCPUFA intake for extended periods have shown inverse associations between intake and cancer risk. A study of over 90 000 subjects in Japan showed a significant, dose-dependent decrease in risk of development of hepatocellular carcinoma in people with a higher fish and n-3 PUFA intake, even in a high-risk group after adjustment for additional risk factors ([@bib33]). Hepatocellular carcinoma is an inflammatory-linked cancer, triggered by hepatitis virus infection and toxin exposure, and therefore the anti-inflammatory action of n-3s may be responsible for the decrease shown. A prospective study over 22 years studying fish intake and colorectal cancer risk in American physicians showed similar results, with lower risk of cancer development associated with higher n-3 PUFA intake ([@bib20]). These associations persisted after controlling for known risk factors and possible confounding issues, indicating that there is a strong probability that the effect was indeed caused by the consumption of n-3-rich foods and supplements. Both these studies and others have proposed the anti-inflammatory properties of n-3 fatty acids as the likely mechanism for cancer prevention ([@bib4]; [@bib20]; [@bib33]). The World Cancer Research Fund/American Institute for Cancer Research (2007) Expert Report provides a comprehensive review of further studies relating to the prevention of cancer through food, nutrition, and physical activity, including marine-derived n-3 LCPUFAs such as EPA and DHA (AICR and WCRF, 2007). Numerous *in vitro* and *in vivo* studies have demonstrated that n-3 LCPUFA supplementation, in particular EPA and DHA, can inhibit tumour growth through a variety of other proposed mechanisms, including apoptosis, inhibition of angiogenesis, and alterations to cell signalling, all of which have been implicated in the reduced risk of cancer development seen in study populations with high n-3 LCPUFA intake ([@bib4]).

Several experimental studies utilising a variety of chemotherapeutic agents and tumour types have reported a greater efficacy of chemotherapy with the addition of n-3 LCPUFA. In particular, EPA and DHA modulate this response via diverse mechanisms ([@bib4]). Eicosapentaenoic acid and DHA have previously been shown to increase tumour sensitivity to irinotecan therapy and protect nontarget tissues, including a reduction of gastrointestinal toxicity ([@bib4]). More recently, [@bib26] have shown that the administration of 2.5 g day^−1^ of an EPA+DHA supplement to non-small cell lung cancer (NSCLC) patients undergoing platinum-based chemotherapy caused a two-fold increase in therapy response rate and clinical benefit when compared with patients undergoing the same treatment without additional supplementation ([@bib27]). Patients in the supplement group were also able to undertake on average an additional 3 weeks of chemotherapy, and showed a trend toward increased survival ([@bib27]). Improved chemotherapy outcomes have been observed in breast cancer patients undergoing anthracycline-based chemotherapy when a daily DHA supplement was highly incorporated into circulating phospholipids ([@bib6]). The potential for DHA supplementation to sensitise tumours to treatment was suggested because of high antitumour activity observed with high incorporation of DHA in plasma phospholipids. This may be due to membrane enrichment with the highly peroxidisable DHA, leading to increased peroxidation of membranes caused by oxidative stress induced by the cancer therapy ([@bib6]; [@bib11]). The addition of n-3 LCPUFA has been demonstrated to improve tumour toxicity, reduce off-target toxicity, and act to protect off-target tissues. Because of reduced symptom burden and toxicity, longer treatment times are achievable, leading to extended survival duration, and providing a strong rationale for the inclusion of marine PUFA as a concurrent treatment during chemotherapy.

Supplementation with marine-sourced n-3 PUFAs has been shown to exert some benefit on the general health and quality of life (QoL) in cancer patients. A recent study in NSCLC patients showed that daily supplementation with EPA/DHA, in conjunction with standard treatment, improved QoL, physical function, cognitive function, and global health status compared with control patients ([@bib39]). The study also demonstrated that patients undergoing the treatment tended to have higher physical activity than the control group. The EPA supplementation in lung cancer patients has also shown improved general well-being after a 60-day period, with patients in one study showing significant improvements in body weight, energy intake, appetite, and QoL ([@bib13]). Patients had improved nutritional status, and a reduction in circulating acute-phase proteins, indicating reduced inflammation, as shown in previously mentioned studies. However, results from a recent study of enteral EPA and DHA supplementation post surgery in oesophagogastric cancer demonstrated that although circulating levels of n-3 fatty acids were increased, there was no improvement in morbidity, mortality, or length of hospital stay ([@bib36]), indicating that the benefit of n-3 LCPUFA supplementation is not universal, and may be dependent upon when supplementation is provided during the progression of cancer or treatment course.

As previously discussed, inflammation can be a key factor in cancer, and poses a critical target for cancer therapy. The importance of the circulating n-3 to n-6 fatty acid ratio in blood has been highlighted by a study in breast cancer survivors investigating the effect of PUFA on multidimensional fatigue and inflammation ([@bib2]). Physical fatigue symptoms and impact were significantly associated with increased inflammation, with higher C-reactive protein (CRP) levels associated with greater risk of fatigue even after adjustment for multiple co-risk factors. Increased n-3 relative to n-6 in the diet was associated with a clinically significant reduction in inflammation, whereas high n-3 intake also correlated with reduced behavioural, sensory and cognitive aspects of fatigue. The reduced risk of fatigue with increased n-3 consumption implies an inflammation-mediated association between PUFA consumption and fatigue in this population. As increased inflammation is associated with decreased survival intervals for breast cancer patients ([@bib2]), this provides an important target for future research. The n-3 LCPUFAs, in particular EPA and DHA, have been implicated to have an inhibitory effect on pro-inflammatory cytokines, subsequently reducing inflammation. Supplementation with EPA/DHA increases acetylcholine levels, in turn blocking the release of cytokines such as tumour necrosis factor-α (TNF-*α*), interlukin-1, and interlukin-6, with the replacement of AA by EPA and DHA causing altered production of eicosanoids towards less inflammatory products ([@bib7]; [@bib3]). Inflammation caused by redox imbalance has also been shown to be reduced by EPA/DHA supplementation via decreased production of ROS by COX-2 and upregulation of antioxidant systems ([@bib3]; [@bib21]). This anti-inflammatory approach is further supported by the use of EPA and DHA in conjunction with Cox-2 inhibitors in supportive cancer care in order to reduce symptom clusters ([@bib8]). Lung cancer patients given either fish oil (1 g, 18% EPA and 12% DHA) and celecoxib or fish oil with placebo over a 6-week period showed significantly improved appetite, less fatigue, and lower CRP levels than at baseline. The group receiving the combined treatment group also showed increased body weight and muscle strength compared with baseline, and lower CRP levels with increased body weight and muscle strength compared with fish oil alone. The addition of celecoxib to fish oil modulates eicosanoid metabolism, reducing symptoms of secondary syndromes in cancer ([@bib8]), in particular those associated with inflammation, and provides a strong argument for the use of fish oil as part of a multimodal therapy for the treatment of these conditions.

There is a high prevalence of depression in cancer patients (10--30%) compared with the general population (5--10%), with depression leading to reductions in drug compliance and effectiveness ([@bib9]). There is some difficulty in distinguishing between reactive demoralisation and clinical depression, or the overlapping symptoms of illness and depression, which may contribute to clinical depression being underrecognised and undertreated in patients with cancer ([@bib29]). However, the increased expression of shared inflammatory cytokine pathways may lead to increased prevalence of clinical depression in a cancer patient population ([@bib29]). As such, treatments that address pro-inflammatory cytokine activity in cancer, such as supplementation with EPA or DHA, may also contribute towards the alleviation of clinical depression in susceptible patients.

Marine PUFAs and secondary cancer complications
===============================================

Complications associated with cancer vary between patients, tumour type, and disease stage, and can take a number of forms including infection, pain, nausea, fatigue, anxiety, and cachexia ([@bib8]).

Cancer cachexia is a complication of cancer that occurs in patients with advanced solid tumour cancers ([@bib38]). Cachexia is a multidimensional condition, characterised by involuntary weight loss of \>5%, that involves a number of tumour and host factors in its progression. These include tumour-induced pro-cachectic and pro-inflammatory responses, systemic inflammation, and altered metabolism, leading to a loss of skeletal muscle and adipose tissue ([@bib12]; [@bib14]), and can severely affect QoL through fatigue, weakness, and reduced physical activity ([@bib38]), with patients facing a poor prognosis ([@bib18]).

The ubiquitin--proteasome pathway is one pathway responsible for the breakdown of proteins, and may be initiated by tumour-derived factors such as TNF-*α* ([@bib35]). Downstream factors such as AA and reactive oxygen species have also been implicated in its induction ([@bib35]). The weight loss occurring in cachexia is also attributed to the loss of adipose tissue via lipolysis. This is initiated by lipid-mobilising factor (LMF), and the tumour and host factor zinc-α~2~-glycoprotein (ZAG) that are overexpressed in cachectic patients ([@bib32]).

In addition to being used as an adjuvant to cancer therapy, n-3 LCPUFAs have been tested to alleviate the symptoms of cancer cachexia ([Table 1](#tbl1){ref-type="table"}). [@bib41]) demonstrated that EPA supplementation was significantly associated with an increase in lean body mass in cachectic patients, a gain that may be attributed to the downregulation of the ubiquitin--proteasome pathway ([@bib38]). The EPA supplementation of 2.2 g day^−1^ over treatment duration has also been shown to assist in the maintenance of weight and muscle mass in NSCLC patients undergoing chemotherapy compared with patients undergoing chemotherapy without EPA supplementation ([@bib27]). The anti-inflammatory properties of EPA have also been implicated in reducing acute-phase proteins, such as CRP, that may contribute to muscle wasting in cachexia ([@bib27]). A study by [@bib18]) showed a significant decrease in CRP levels in cachectic patients supplemented with EPA, whereas the levels in control group increased.

In studies of varying cancer types, EPA has shown significant ([@bib18]) and nonsignificant ([@bib15]; [@bib41]) increases in body weight, indicating that the type of cancer may also play a role in EPA responsiveness, with gastrointestinal cancer patients gaining a significant amount of weight compared with the lung cancer patients ([@bib15]). The weight gain may be attributed to a number of different mechanisms, including increases in lean body mass and the downregulation of ZAG ([@bib32]) via the interference with glucocorticoid signalling ([@bib38]), reducing the degradation of adipose tissue.

Despite several clinical studies showing no statistically significant gain in weight and lean body mass, it is important to note that many studies do report improved QoL ([@bib15]; [@bib39]). In a study of EPA and DHA, patients reported high level of improvements in pain and overall health and a significant increase in body weight ([@bib37]). Increased total energy expenditure and physical activity levels have been observed in patients taking EPA supplements in trials, indicating improved physical capacity ([@bib23]; [@bib39]). Any improvement the physical activity, ability to perform daily tasks, fatigue, weakness, and overall health of patient greatly enhances their QoL, and leads to improved prognosis ([@bib23]; [@bib12]; [@bib39]). Thus, n-3 LCPUFAs may be a consideration as part of a multimodal approach to treat cancer and associated complications such as cachexia ([@bib10]).

Limitations of marine PUFA use
==============================

Although marine PUFAs have been shown to have considerable potential to prevent and augment the treatment of cancer and complications such as cachexia, there are still a number of limitations associated with their use in cancer patients. Because of a significant number of cancer patients experiencing nausea, the consumption of therapeutic doses of fish oil (\>3 g per day) or more purified EPA/DHA (\>2 g EPA, \>1.4 g DHA per day) may be impractical, because of the commonly experienced side effect of 'fishy\' reflux experienced by many patients consuming fish oil or EPA/DHA supplements. In addition, investigations by [@bib31] raised the question as to whether all PUFAs provide benefit, particularly in patients receiving chemotherapy ([@bib31]). They suggest that the PUFAs 12-oxo-5,8,10-heptadecatrienoic acid (KHT (n-6)) and hexadeca-4,7,10,13-tetraenoic acid (16:4(n-3)) may be involved in the induction of resistance to chemotherapy. Although these compounds may have a profound pharmacological effect, others have described their abundance to be low, with analyses of various fish oil preparations placing them between 0% and 1.56% of total lipid content ([@bib28]; [@bib42]). [@bib24]) have previously highlighted the inconsistencies presented by these claims when compared with the published literature, and the concern that recommending the reduction of essential fatty acids may have a detrimental effect in this patient population. The discovery that KHT and 16:4(n-3) may play a role in chemotherapy resistance highlights that there is a need for supplementation of marine PUFA supplements to be carefully assessed, with a focus on promoting purified n-3 LCPUFA supplements over less refined whole fish oil, rather than the broad discouragement of this often beneficial augmentation to treatment in patients undergoing chemotherapy.

Conclusions
===========

Polyunsaturated fatty acids derived from marine sources, including EPA and DHA, are widely consumed as supplements within the community, including cancer patients. The prescription of n-3 LCPUFAs in a therapeutic context is also increasing in patients receiving treatment for a range of cancer types. There is also now sufficient literature to suggest that the use of supplements containing EPA and DHA may have potential as an effective adjuvant to chemotherapy treatment and may help ameliorate some of the secondary complications associated with cancer. Although this review was not exhaustive, our investigations indicate that supplementation with fish oil (\>3 g per day) or EPA/DHA (\>1 g EPA and \>0.8 g DHA per day) is associated with positive clinical outcomes. However, other components of fish oil may be detrimental to cancer treatment, and further research is still required to determine the mechanisms by which both marine-derived n-3 PUFAs and other fish-oil derived compounds are mediating their effects.
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  [@bib2]      Breast cancer survivors (*n*=633) completed food frequency questionnaire and blood test (30 months post diagnosis), Piper Fatigue Scale, and Short Form-36 vitality scale (39 months post diagnosis).                                                                                                                                                                                                            To investigate the effects of n-3 and n-6 PUFA intake on fatigue and inflammation in breast cancer survivors. By measuring n-3 and *n*-6 intake, fatigue using a piper fatigue scale and analysing CRP levels.                                                                                                                                                                        High CRP increased risk of fatigue. Higher n-6 intake compared with n-3 intake associated with higher CRP and higher risk of fatigue. Reduced risk of fatigue with increased n-3 consumption implies an inflammation-mediated association between PUFA consumption and fatigue in this population.
  [@bib5]      Paediatric patients with a range of malignant cancers (*n*=52) were randomised to a prospective, single-centre, open-label study to either: E group: Protein and energy-rich oral supplement containing 2.18 g EPA (*n*=33) or C group: Patients usual dietary care (*n*=19). Patients started treatment from clinical diagnosis with patients continuing for 3 months and a subgroup continuing for 6 months.   To assess the effects of an energy-dense oral supplement containing EPA on body weight and remission rates in paediatric patients with malignant cancers, by measuring body weight and remission rates.                                                                                                                                                                               Remission rates at 3 months of E group were significantly higher compared with C group. The E group experienced significantly less loss of body weight and BMI compared with C group. Important to note that the above outcomes were predominantly seen in leukaemia patients compared with solid cancer patients.
  [@bib6]      Open-label, single-arm phase II study assessing safety and efficacy in metastatic breast cancer patients (*n*=25) undergoing chemotherapy. DHA (1.8 g) daily with anthracycline-based chemotherapy.                                                                                                                                                                                                              To investigate the efficacy and safety of adding DHA to an oral supplement ROS generating chemotherapy treatment, by measuring response rate and survival of breast cancer patients.                                                                                                                                                                                                  No adverse side effects associated with DHA supplementation during chemotherapy. Higher plasma DHA concentrations were associated with increased clinical benefit and extended survival duration. The DHA supplementation during chemotherapy may improve treatment response via chemosensitisation of tumours by DHA membrane incorporation and improve survival in breast cancer patients.
  [@bib8]      Patients with advanced non-small cell lung cancer (*n*=22) were randomised to an unblinded, placebo-controlled study to receive 6 weeks of treatment in either: E group: fish oil (18% EPA and 12% DHA) 6 g and celecoxib (*n*=10). C group: fish oil (18% EPA and 12% DHA) 6 g and placebo (*n*=12).                                                                                                            To measure the effects of a multimodal treatment (including fish oil) on a group of Systemic Immune-Metabolic Syndrome (SIMS) symptoms in non-small cell lung cancer patients. Symptoms assessed included cachexia anorexia, nausea, fatigue, and appetite.                                                                                                                           E group showed a significant increase in body weight compared with baseline, C group showed a decrease in body weight. Appetite significantly increased in both groups. Fatigue and CRP levels significantly decreased in both groups.
  [@bib15]     Patients with advanced lung or gastrointestinal cancer (*n*=518) were randomised to a double-blind, placebo-controlled 8-week study of daily treatment. E1: 2 g EPA (*n*=175), E2: 4 g EPA (*n*=172), C group (*n*=171).                                                                                                                                                                                         To examine the effects of EPA treatment on cachexia in cancer patients, by measuring body weight and composition, CRP, albumin, appetite, physical functioning, and Karnofsky performance status.                                                                                                                                                                                     Nonsignificant weight gain of 1.2 kg in E1 and 0.3 kg in E2. It is important to note that patients with GI cancer gained significant amount of weight compared with lung cancer patients who did not. E1 showed a nonsignificant gain of 0.9 kg in lean body mass and E2 decreased by 0.1 kg. Physical function compared with control improved significantly by 7% in E1 and decreased by 5% in E2.
  [@bib16]     Patients with advanced inoperable non-small cell lung cancer and undertaking chemotherapy were randomised to a multicentre, double-blind study to receive 66 days of daily treatment of: E group: 4 capsules of 510 mg EPA and 340 mg of DHA (*n*=13). C group: 4 capsules of 850 mg olive oil (*n*=14).                                                                                                         To examine the effects of EPA+DHA on inflammatory condition, oxidative and nutritional status on lung cancer patients undergoing chemotherapy, by measuring body weight and oxidative indicators: ROS and hydroxynonenal levels in plasma, and inflammatory parameters; CRP, IL-6, PGE~2~ and TNF-*α* levels.                                                                         C group had higher levels of CRP, IL-6, TNF-*α*, and PGE~2~ compared with E group, with significant differences in CRP and IL-6 levels. Hydroxynonenal and ROS levels were significantly increased in both the C groups and decreased in both E groups.
  [@bib18]     Patients with small cell lung cancer and non-small cell lung cancer undergoing chemotherapy (*n*=46) were randomised to a blind, placebo-controlled study to receive 60 days of treatment with either: E group: energy-rich oral supplement containing 2.2 g of EPA (*n*=26). C group: energy-rich oral supplement minus EPA (*n*=20).                                                                           To evaluate the influence of an EPA-enriched, energy-dense oral supplement on inflammatory and nutritional status and on the QoL of lung cancer patients undergoing chemotherapy, by measuring body weight, inflammatory parameters; prealbumin, transferring, and CRP and QoL using a self-administered EORTC questionnaire.                                                         Body weight in E group significantly increased by a median of 0.9 kg, compared with control that decreased at 30 days and then returned to baseline median. Both groups showed increases in QoL functioning status and decrease of QoL symptom status, with significant results in E group. Significant decrease in E group in CRP levels with an increase in control.
  [@bib20]     A 22-year prospective study of American physicians with annual follow-up, including food frequency questionnaire and reporting of new diagnosis of colorectal cancer (*n*=22 071).                                                                                                                                                                                                                               To examine the relationship of n-3 and n-6 PUFAs intake with colorectal cancer risk by analysing food frequency diaries and diagnosis of colorectal cancer.                                                                                                                                                                                                                           Fish intake inversely correlated with colorectal cancer risk. Intake of n-3 PUFA and fish may decrease the risk of colorectal cancer development.
  [@bib22]     Patients with a range of cancers (*n*=39) partook in an open nonrandomised phase II study and received a multimodal treatment consisting of: diet with high polyphenol content, antioxidant treatment (ALA (300 mg), Vit. E (400 mg), Vit. A (30 000 IU), and Vit. C (500mg)), pharmaconutritional support; EPA 2.2 g and DHA 0.92 g), progestagen and Cox-2 inhibitor.                                          To assess the efficacy and safety of a pharmaconutritional supplement containing antioxidants and drugs, in advanced cancer patients with from cancer-related anorexia-cachexia syndrome. Efficacy variables of disease stability, nutritional functions of LBM, appetite and grip strength, inflammatory cytokines, and EORTC questionnaires were used to assess these parameters.   Significant increase in body weight, LBM, and appetite. The IL-6 and TNF-*α* significantly decreased. Significant improvement in QoL and fatigue. Spearman rank test showed significant correlation between LBM differences and IL-6 levels.
  [@bib27]     Open-label, non-small cell lung cancer patients undergoing first-line chemotherapy received combination of fish oil (2.5 g EPA and DHA per day)+chemotherapy (*n*=15) or standard of care+chemotherapy (*n*=31).                                                                                                                                                                                                 To assess if the combination of fish oil and chemotherapy was beneficial over the standard of care with regard to response rate and clinical benefit from chemotherapy in patients with non-small cell lung cancer.                                                                                                                                                                   Fish oil group had increased response rate and clinical benefit compared with the control group. The incidence of dose-limiting toxicity did not differ between groups. The 1-year survival tended to be greater in the fish oil group. Supplementation with fish oil increased efficacy of first-line chemotherapy for non-small cell lung cancer compared with standard of care alone, and may contribute to increased survival duration in that population.
  [@bib25]     Patients with non-small cell lung cancer and naive to or undergoing first-line chemotherapy consented to receive platinum-based chemotherapy for \>6 weeks, with fish oil (2.2 g EPA per day; *n*=16) supplementation, or standard of care (*n*=24).                                                                                                                                                             To assess effect of EPA intervention, in comparison with standard of care/no EPA intervention, on weight, and body composition relating to skeletal muscle and adipose tissue from initiation to completion of chemotherapy.                                                                                                                                                          Patients in the standard of care group experienced significantly greater weight loss than the fish oil group, in which patients with the greatest increase in plasma EPA concentration experienced greatest muscle gains. Thus, 69% of EPA group increased or maintained muscle mass compared with 29% in standard of care group. No difference in adipose was observed. Supplementation of 2.2 g EPA per day provides benefits over standard of care in maintenance of weight and body mass during chemotherapy in this patient population.
  [@bib30]     Patients with advanced colorectal cancer receiving chemotherapy (*n*=23) partook in an open-label, phase II study and received 9 weeks of treatment, consisting of a protein and energy-rich oral supplement containing 2.18 g EPA and 0.92 g DHA.                                                                                                                                                               To assess the effects of EPA (contained in an energy-rich oral supplement) on nutritional and inflammatory status, QoL, plasma phospholipids, and cytokine profiles, in patients with advanced colorectal cancer who are undergoing chemotherapy, by measuring body weight and composition, CRP levels, dietary intake, plasma phospholipid, and cytokine levels.                     Significant increase in mean body weight by 2.5 kg over 9 weeks. The LBM increased nonsignificantly by 1.4 kg. The CRP levels increased from baseline by 14.9 mg l^−1^ at 3 weeks and at 9 weeks had reduced back to 1.2 mg l^−1^ above baseline. Nonsignificant improvement in QoL at 9 weeks. The QoL measure for energy had significantly improved.
  [@bib33]     Population-based cohort study (*n*=90 296). Self-administered questionnaire at baseline and 5-year follow-up survey including food frequency questionnaire. In all, 33 392 subjects provided blood samples.                                                                                                                                                                                                      To investigate the association of fish and n-3 PUFA consumption and hepatocellular carcinoma by analysing food frequency questionnaires and assessing patient blood samples.                                                                                                                                                                                                          Among all patients, consumption of n-3 PUFA-rich fish and supplements was inversely associated with hepatocellular carcinoma in a dose-dependent manner. Reduced hepatocellular carcinoma risk may be linked to decreased inflammation caused by higher n-3 PUFA intake.
  [@bib36]     Subtotal oesophagectomy and total gastrectomy oesophagogastric cancer patients (*n*=192) randomised to n-3 enteral immune-enhancing diet or standard enteral nutrition for 7 days before and after surgery, or to postoperative supplementation alone (control group).                                                                                                                                           To assess the effect of n-3 fatty acids on clinical outcome and immune function post oesophagogastric cancer surgery by measuring morbidity and mortality rates, fatty acid concentrations, and monocyte and activated T-lymphocyte levels.                                                                                                                                           No differences in morbidity, mortality, or hospital stay between groups. Plasma n-3 increased in the enteral immunoenhancing diet. No difference between expression of monocytes or activated T lymphocytes between groups. n-3 supplementation for 7 days pre- and post-oesophagogastic cancer surgery had no overall effect on immune response or clinical outcomes despite increased plasma n-3 levels.
  [@bib37]     Cancer patients with varying cancers (*n=*31) partook in an open-label, single-arm study, and received 6 weeks of treatment of 3 capsules daily of 500 mg capsule containing 176.5 mg EPA and 282.5 mg DHA.                                                                                                                                                                                                      To assess the effects of a marine phospholipids (\>50% containing EPA and DHA) of cachectic weight loss, appetite, QoL, and fatty acid profile of blood plasma by measuring body weight, appetite, and QoL by self-administered questionnaires, and cytokine and fatty acid levels in blood of patients with various cancer types.                                                    Patients reported on the subjective significance questionnaire, high levels of improvement in pain reduction, and overall health, with moderate to high levels in physical scores. Baseline weight compared with end of study showed a significant increase; however, some patients were gaining weight before study. The CRP showed a slight decrease, and IL-6 and TNF-*α* increased but not significantly.
  [@bib39]     Patients with stage III non-small cell lung cancer (*n=*40) were randomised to a double-blind, placebo-controlled, study consisting of 5 weeks of treatment of: E group: protein and energy-rich oral supplement containing 2.02 g EPA and 0.92 g DHA, *n=*20. C group: Isocaloric oral supplement, *n=*20.                                                                                                      To investigate the effects of an oral nutrient supplement containing n-3 fatty acids on QoL, performance status, handgrip strength, and physical activity in patients with NSCLC, by measuring QoL using the EORTC and by using specific equipment to measure grip strength and physical activity.                                                                                    Group E showed significant increases in physical function, cognitive function, and a reduction in nausea/vomiting. n-3 PUFAs may improve QoL, performance status, and physical activity in patients with non-small cell lung cancer undergoing multimodality treatment.
  [@bib41]     Patients with squamous cell cancer of the head and neck who were undergoing major resection surgery (*n=*38), partook in a single-centre, open-label, single-arm study, and received treatment 2 weeks before surgery and during, consisting of: protein and energy-dense oral supplement containing 2.16 g EPA and 0.92 g DHA.                                                                                  To assess the effects of an oral supplement containing EPA on cancer-associated weight loss mediated by an inflammatory response to cancer on body weight and composition by measuring body weight and composition.                                                                                                                                                                   Mean weight from trial entry to hospital admission was 0.71 kg and from admission to discharge was 0.66 kg; these results were not significant. Lean body mass had a significant increase during admission to discharge, with a mean gain of 3.2 kg. Fat mass also showed a significant decrease of 3.19 kg during the same period.

Abbreviations: ALA=*α*-lipoic acid; BMI=body mass index; Cox-2=cyclooxygenase-2; CRP=C-reactive protein; DHA=docosahexaenoic acid; EORTC=European Organisation for Research and Treatment of Cancer; EPA=eicosapentaenoic acid; GI=gastrointestinal; IL-6= interlukin-6; LBM=lean body mass; LCPUFA=long-chain polyunsaturated fatty acid; NSCLC=non-small cell lung cancer; PGE~2~= prostaglandin E2; QoL=quality of life; ROS=reactive oxygen species; TNF-*α*=tumour necrosis factor-α.
